晚期乳腺癌DC-CIK联合化疗临床疗效及安全性Meta分析

发布时间：2018-04-01 15:37

本文选题：DC-CIK　切入点：晚期乳腺癌　出处：《中华肿瘤防治杂志》2017年10期

【摘要】：目的化疗为晚期乳腺癌主要的治疗手段,疗效欠佳,DC-CIK细胞具有杀瘤活性高、杀瘤谱广的优点,已成为肿瘤治疗领域的热点。本研究分析了树突状细胞共培养细胞因子诱导的杀伤细胞(dendritic cell-cytokine-induced killer cell,DC-CIK)联合化疗治疗晚期乳腺癌的临床疗效及安全性,同时评价患者的免疫功能。方法采用计算机检索万方数据库、相关期刊论文(CNKI)、维普期刊全文数据库(VIP)和PubMed等数据库2000-01-01-2016-02-23的相关文献,收集所有DC-CIK联合化疗与单纯化疗治疗晚期乳腺癌的随机对照试验(randomized controlled trials,RCT)。结合研究特点对纳入研究进行质量评价后,采用RevMan 5.2进行Meta分析。结果共纳入12个RCT,共计1 007例患者。Meta分析结果显示,与单纯化疗组比较,DC-CIK联合化疗组临床疗效有所提高,包括客观反应率(objective response rate,ORR,OR=1.82,95%CI为1.31~2.55,P=0.000 4)、疾病控制率(disease control rate,DCR,OR=1.91,95%CI为1.28~2.85,P=0.002)以及免疫功能(治疗后血清中T淋巴细胞亚群CD3~+、CD4~+与NK),不良反应的发生率(OR=1.82,95%CI为1.31~2.55,P=0.000 4)有所下降。临床疗效观察指标显示无发表偏倚。结论在晚期乳腺癌治疗中,与单纯化疗比较,DC-CIK联合化疗能提高临床疗效,降低不良反应发生,同时对患者的免疫功能有所改善。
[Abstract]:Objective chemotherapy is the main treatment method for advanced breast cancer, and DC-CIK cells have the advantages of high tumor killing activity and wide tumor killing spectrum. In this study, the clinical efficacy and safety of dendritic cell coculture induced killer cell cell-cytokine-induced killer DC-CIK in the treatment of advanced breast cancer were analyzed. Methods the relevant literatures of Wanfang database, CNKI database, Weip periodical full-text database and PubMed database, such as Wanfang database, Chinese periodical full-text database and PubMed database, were searched by computer. To collect all randomized controlled trialsof DC-CIK combined chemotherapy and chemotherapy alone for the treatment of advanced breast cancer. A total of 1 007 patients were included in the Meta analysis. The results showed that compared with the simple chemotherapy group, the clinical efficacy of the DC-CIK combined chemotherapy group was improved. The incidence of adverse reactions was decreased, including objective response rate (1.8295 CI = 1.31n 2.55P0.0004), disease control rate and disease control rate (CI = 1.2852.85P0.002) and immune function (CD3 ~ + CD4 ~ + and NKN). The incidence of adverse reactions was 1.8295 CI = 1.31 / 2.55P0.0004). The clinical curative effect was observed. Conclusion in the treatment of advanced breast cancer, there is no publication bias. Compared with chemotherapy alone, DC-CIK combined chemotherapy can improve the clinical efficacy, reduce the occurrence of adverse reactions, and improve the immune function of the patients.
【作者单位】：新疆医科大学第一附属医院肿瘤中心;
【基金】：国家自然科学基金(81560388)
【分类号】：R737.9

【相似文献】